Bruker (BRKR)
(Delayed Data from NSDQ)
$63.32 USD
-0.05 (-0.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $63.32 0.00 (0.00%) 5:08 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
BRKR 63.32 -0.05(-0.08%)
Will BRKR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BRKR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BRKR
Bruker (BRKR) Up 6.8% Since Last Earnings Report: Can It Continue?
Should You Consider Retaining Bruker Stock in Your Portfolio Now?
BRKR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia
Bruker (BRKR) Reliance on International Sales: What Investors Need to Know
Bruker (BRKR) Partners With NovAliX to Boost Drug Discovery
Other News for BRKR
Jefferies Sticks to Its Buy Rating for Bruker (BRKR)
Foot Locker trips after earnings, Kohl's posts Q2 beat: Morning Buzz
What's Driving Insulet Corp's Surprising 12% Stock Rally?
Illumina upgraded, Fiserv initiated: Wall Street's top analyst calls
Wells Fargo starts tools and diagnostics group with positive bias